Richard Frank, MD, MHSA, Chief Medical Officer at Vida Health, spoke to Medical News Today about how orforglipron may expand access to GLP-1s: The choice between a pill and an injectable comes down to patient preference and potency. The injectables are clearly more potent but require a weekly injection
Diabetes Action Canada supported this research by providing access to the NDR and advocating for the inclusion of patient voices and collaborating with stakeholders to improve access to these innovative therapies.
Common Side Effects of Semaglutide Like any medication, semaglutide can cause side effects
It is crucial to consult with medical doctors or qualified functional medicine practitioners to address specific health concerns and obtain personalised guidance tailored to individual needs
Cagrilintide is a synthetic long-acting amylin analog developed by Novo Nordisk for once-weekly subcutaneous administration
GLP-1 medications are approved for adults who have a body mass index (BMI) of 30 or higher, or a BMI of at least 27 plus a weight-related medical condition, such as the following: Type 2 diabetes High blood pressure High cholesterol Obstructive sleep apnea Cardiovascular disease that increases the risk of heart attack or stroke MASH, or metabolic dysfunctionassociated steatohepatitis, a form of liver inflammation Avlin Imaeda, MD, PhD, a Yale Medicine gastroenterologist who is board-certified in obesity medicine, notes that qualifying for the medication based on heart disease aloneoften necessary for insurance coveragecan be challenging